October 21, 2015 – Contextual Genomics
Vancouver, BC – October 21, 2015 – Contextual Genomics, developers of genomics-based cancer tests, has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP). The CAP Laboratory Accreditation, the highest laboratory standards accreditation internationally, is recognized by the U.S. federal government as equal-to or more-stringent-than the government’s own laboratory inspection programs.
“It is Contextual’s goal to make high quality genomics-based cancer testing widely available and the CAP accreditation ensures our laboratory meets the highest standards in providing accurate and safe testing,” commented Chris Wagner, President and CEO of Contextual Genomics. “We believe Contextual Genomics is the first CAP accredited company in Canada to offer next generation sequencing based genomic cancer testing. As a leader in this area, it is important to us to follow the standards set by CAP.”
During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
About the College of American Pathologists: www.cap.org
As the leading organization with more than 18,000 board-certified pathologists, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP Laboratory Improvement Programs, initiated 65 years ago, currently have customers in more than 100 countries, accrediting 7,700 laboratories and providing proficiency testing to 20,000 laboratories worldwide.
About Contextual Genomics: www.contextualgenomics.com
Contextual Genomics is developing a novel suite of standardized genomics-based cancer tests to identify a patient’s tumour profile. This precision in cancer diagnosis allows healthcare professionals to more accurately determine the most effective treatment options for the patient using a single test. The company’s first products are actionable molecular tests that unify multiple companion diagnostics for multiple medicines into a single test that guides diagnosis and treatment of cancer.
Led by global leaders in molecular diagnostics, genomics and bioinformatics who have unparalleled expertise in genomic assay development, Contextual Genomics aims to bring patients a gold standard in molecular diagnostics that will lead to advanced services in personalized cancer care.
For further information:
Chris Wagner, President and CEO
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.